Evonik’s EUDRACAP colon functional capsules are now available produced under good manufacturing practice (GMP).

Launched last year, EUDRACAP colon is a functional, ready-to-fill capsule specifically designed to target the ileo-colonic region. The capsule meets the growing demand for precise delivery of sensitive active ingredients – such as live biotherapeutic products (LBPs) – used to treat or prevent a wide range of diseases such as obesity, infections and cancer.

“Enabling the oral delivery of sensitive molecules opens new opportunities for the pharmaceutical industry. I am delighted that our customers can now work on clinical and commercial phases for innovative, breakthrough drugs,” said Thilo Krapfl, Head of Oral Drug Delivery Solutions at Evonik Health Care.

EUDRACAP colon can be used for the delivery of sensitive active ingredients such as live biotherapeutics, oral biologics, proteins, peptides and nucleotides (RNA). These actives are used in the formulation of innovative drugs for the treatment of severe conditions such as obesity, HIV, or Cystic Fibrosis, as well as for local delivery such as for colorectal cancer and infections. There are currently more than 700 oral drug development programs using novel active ingredients. In fact, these new drug candidates make up around a third of all new oral drug developments in the pipeline.